# Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant

> **NCT00354120** · PHASE2,PHASE3 · COMPLETED · sponsor: **Gruppo Italiano Trapianto di Midollo Osseo** · enrollment: 121 (actual)

## Conditions studied

- Acute Myeloblastic Leukemia
- Lymphoblastic Leukemia
- Myelodysplasia
- Chronic Myeloid Leukemia
- Myelofibrosis
- Lympho-proliferative Diseases

## Interventions

- **DRUG:** Alentuzumab
- **DRUG:** Globulina antilinfocitaria

## Key facts

- **NCT ID:** NCT00354120
- **Lead sponsor:** Gruppo Italiano Trapianto di Midollo Osseo
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2023-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00354120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00354120, "Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00354120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*